| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Instituto de Biología y Medicina Experimental (IBYME) (R.P.C., C.J.P., M.S., E.H.C., R.S., P.V.E.), Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires C1428ADN, Argentina; Research Area (A.U., G.P., E.B.d.K.J.), Institute of Oncology Angel H. Roffo, University of Buenos Aires, C1417DTB Buenos Aires, Argentina; and Department of Molecular and Cellular Biology and Pathology (D.P.E., V.B.), Baylor College of Medicine, Houston, Texas 77030
Address all correspondence and requests for reprints to: Patricia V. Elizalde, Ph.D., Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME), Vuelta de Obligado 2490, Buenos Aires 1428, Argentina. E-mail: elizalde{at}dna.uba.ar.
Accumulating evidence indicates that progestins are involved in controlling mammary gland tumorigenesis. Here, we assessed the molecular mechanisms of progestin action in breast cancer models with different phenotypes. We examined C4HD cells, an estrogen (ER) and progesterone (PR) receptor-positive murine breast cancer model in which progestins exert sustained proliferative response, the LM3 murine metastatic mammary tumor cell line, which lacks PR and ER expression, and human PR null T47D-Y breast cancer cells. In addition to acting as a transcription factor, PR can also function as an activator of signaling pathways. To explore which of these two functions were involved in progestin responses, reconstitution experiments in the PR-negative models were performed with wild-type PR-B, with a DNA binding mutant C587A-PR, and with mutant PR-BmPro, which lacks the ability to activate cytoplasm signaling pathways. We found that in a cell context either ER-positive or -negative, progestins induced cell growth and modulation of matrix metalloproteinases-9 (MMP-9) and -2 (MMP-2), and urokinase-type plasminogen activator (uPA) activities, via MAPK and phosphatidylinositol 3-kinase/Akt pathways, in cells expressing wild-type PR-B or DNA binding mutant C587A-PR. In contrast, in cells expressing mutant PR-BmPro, progestins did not induce growth. We also found that unliganded PR expression conferred breast cancer cells an in vitro less proliferative phenotype, as compared with cells lacking PR expression. Modulation of this behavior occurred when PR was functioning either as transcription factor or as signaling activator. Finally, we for the first time demonstrated that progestins favor development of breast tumor metastasis via PR function as activator of signaling pathways. Our present findings provide mechanistic support to the design of a novel therapeutic intervention in PR-positive breast tumors involving blockage of PR capacity to activate cytoplasmic signaling.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
M. E. Schmidt, K. Steindorf, E. Mutschelknauss, T. Slanger, S. Kropp, N. Obi, D. Flesch-Janys, and J. Chang-Claude Physical Activity and Postmenopausal Breast Cancer: Effect Modification by Breast Cancer Subtypes and Effective Periods in Life Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3402 - 3410. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Glaser, S. DeMorrow, H. Francis, Y. Ueno, E. Gaudio, S. Vaculin, J. Venter, A. Franchitto, P. Onori, B. Vaculin, et al. Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanisms Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G124 - G136. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-D. Fu, M. Flamini, A. M. Sanchez, L. Goglia, M. S. Giretti, A. R. Genazzani, and T. Simoncini Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin Mol. Hum. Reprod., April 1, 2008; 14(4): 225 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |